1
|
Metlock FE, Addison S, McKoy A, Yang Y, Hope A, Joseph JJ, Zhang J, Williams A, Gray DM, Gregory J, Nolan TS. More than Just a Number: Perspectives from Black Male Participants on Community-Based Interventions and Clinical Trials to Address Cardiovascular Health Disparities. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2024; 21:449. [PMID: 38673360 PMCID: PMC11050149 DOI: 10.3390/ijerph21040449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 03/18/2024] [Accepted: 03/22/2024] [Indexed: 04/28/2024]
Abstract
BACKGROUND Black Americans remain significantly underrepresented and understudied in research. Community-based interventions have been increasingly recognized as an effective model for reckoning with clinical trial participation challenges amongst underrepresented groups, yet a paucity of studies implement this approach. The present study sought to gain insight into Black male participants' perception of clinical trials before and after participating in a community-based team lifestyle intervention in the United States. METHODS Black Impact, a 24-week community-based lifestyle intervention, applied the American Heart Association's Life's Simple 7 (LS7) framework to assess changes in the cardiovascular health of seventy-four Black male participants partaking in weekly team-based physical activities and LS7-themed education and having their social needs addressed. A subset of twenty participants completed an exit survey via one of three semi-structured focus groups aimed at understanding the feasibility of interventions, including their perceptions of participating in clinical trials. Data were transcribed verbatim and analyzed using a content analysis, which involved systematically identifying, coding, categorizing, and interpreting the primary patterns of the data. RESULTS The participants reported a positive change in their perceptions of clinical trials based on their experience with a community-based lifestyle intervention. Three prominent themes regarding their perceptions of clinical trials prior to the intervention were as follows: (1) History of medical abuse; (2) Lack of diversity amongst research teams and participants; and (3) A positive experience with racially concordant research teams. Three themes noted to influence changes in their perception of clinical trials based on their participation in Black Impact were as follows: (1) Building trust with the research team; (2) Increasing awareness about clinical trials; and (3) Motivating participation through community engagement efforts. CONCLUSIONS Improved perceptions of participating in clinical trials were achieved after participation in a community-based intervention. This intervention may provide a framework by which to facilitate clinical trial participation among Black men, which must be made a priority so that Black men are "more than just a number" and no longer "receiving the short end of the stick".
Collapse
Affiliation(s)
- Faith E. Metlock
- Johns Hopkins School of Nursing (Formerly The Ohio State University College of Nursing), Baltimore, MD 21205, USA;
| | - Sarah Addison
- Washington University School of Medicine (Formerly The Ohio State University College of Medicine), St. Louis, MO 63110, USA;
| | - Alicia McKoy
- OhioHealth (Formerly The Ohio State University Center for Cancer Health Equity), Columbus, OH 43202, USA;
| | - Yesol Yang
- The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA; (Y.Y.); (J.Z.)
| | - Aarhea Hope
- Nell Hodgson Woodruff School of Nursing (Formerly The Ohio State University College of Nursing), Atlanta, GA 30322, USA;
| | - Joshua J. Joseph
- The Ohio State University College of Medicine, Columbus, OH 43210, USA; (J.J.J.); (A.W.)
| | - Jing Zhang
- The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA; (Y.Y.); (J.Z.)
| | - Amaris Williams
- The Ohio State University College of Medicine, Columbus, OH 43210, USA; (J.J.J.); (A.W.)
| | - Darrell M. Gray
- Gray Area Strategies LLC (Formerly The Ohio State University College of Medicine), Columbus, OH 43210, USA;
| | - John Gregory
- The African American Male Wellness Agency, National Center for Urban Solutions, Columbus, OH 43205, USA;
| | - Timiya S. Nolan
- University of Alabama at Birmingham Heersink School of Medicine (Formerly The Ohio State University College of Nursing and The Ohio State University Comprehensive Cancer Center), Birmingham, AL 35233, USA
| |
Collapse
|
2
|
LaPlant HW, Francis-Edoziuno C, Guan Z, Aderibigbe T, Chang X, Alhabodal AS, Delaney K, Scott D, Marshall-Crim M, Freytes I, Henderson WA, Walsh S, Lucas RF. Retention and the Intersection of Structural Inequities in a Breastfeeding Intervention Study. MEDRXIV : THE PREPRINT SERVER FOR HEALTH SCIENCES 2024:2024.03.15.24304355. [PMID: 38559187 PMCID: PMC10980120 DOI: 10.1101/2024.03.15.24304355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/04/2024]
Abstract
Introduction Women below the poverty threshold have lower representation and retention in breastfeeding studies. Methods A secondary analysis of a longitudinal randomized controlled self-management for breast and nipple pain during breastfeeding study. Participants completed online surveys at discharge, weeks 1, 2, 3, 6, 9, 12, 18, and 24, with face-to-face interviews at 6 and 24 weeks. Text messages were sent to participants when modules and surveys were due. Retention was assessed in R with descriptive statistics, Mann-Whitney, Pearson's chi-square, and Cox Proportional Hazard Regression. Results Two hundred and forty-four women (89 ≤$50,000 and 155 >$50,000) were recruited. Retention rates at 1 (93%), 2 (87%), 6 (82%), 9 (77%) and 24 (72%) weeks. For women of low income compared to those of high income there was a hazard ratio (HR) of 2.5 (p=0.0001) for retention. For non-Hispanic Black and Hispanic women compared to the combined non-Hispanic White and Other group, HRs for retention were 3.3 and 2.6 respectively (p=0.0001). Adjustment for age in the final hazard regression model of income, age, race and ethnicity decreased the HR for women of low income to 1.6 and HRs for non-Hispanic Black and Hispanic women to 2.1 and 1.9, respectively (p=.0001). However, none of the individual factors in the model achieved statistical significance. Discussion Retention in breastfeeding studies impacts breastfeeding duration, a key lifelong preventative health behavior. Despite accessible study design, retention of women desiring to breastfeed was adversely affected by the intersection of income, race and ethnicity, and age.
Collapse
Affiliation(s)
| | | | - Zhe Guan
- Department of Statistics, University of Connecticut
| | | | | | | | | | - Dana Scott
- Obstetrics and Gynecology Unit, Breast Health and Cancer Genetics, University of Connecticut Health Center
| | | | | | | | | | | |
Collapse
|
3
|
Allen CG, Olstad DL, Kahkoska AR, Guan Y, Ramos PS, Steinberg J, Staras SAS, Lumpkins CY, Milko LV, Turbitt E, Rahm AK, Saylor KW, Best S, Hatch A, Santangelo I, Roberts MC. Extending an Antiracism Lens to the Implementation of Precision Public Health Interventions. Am J Public Health 2023; 113:1210-1218. [PMID: 37651661 PMCID: PMC10568499 DOI: 10.2105/ajph.2023.307386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/06/2023] [Indexed: 09/02/2023]
Abstract
Precision public health holds promise to improve disease prevention and health promotion strategies, allowing the right intervention to be delivered to the right population at the right time. Growing concerns underscore the potential for precision-based approaches to exacerbate health disparities by relying on biased data inputs and recapitulating existing access inequities. To achieve its full potential, precision public health must focus on addressing social and structural drivers of health and prominently incorporate equity-related concerns, particularly with respect to race and ethnicity. In this article, we discuss how an antiracism lens could be applied to reduce health disparities and health inequities through equity-informed research, implementation, and evaluation of precision public health interventions. (Am J Public Health. 2023;113(11):1210-1218. https://doi.org/10.2105/AJPH.2023.307386).
Collapse
Affiliation(s)
- Caitlin G Allen
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Dana Lee Olstad
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Anna R Kahkoska
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Yue Guan
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Paula S Ramos
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Julia Steinberg
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Stephanie A S Staras
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Crystal Y Lumpkins
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Laura V Milko
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Erin Turbitt
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Alanna K Rahm
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Katherine W Saylor
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Stephanie Best
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Ashley Hatch
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Isabella Santangelo
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| | - Megan C Roberts
- Caitlin G. Allen and Ashley Hatch are with the Department of Public Health Sciences, College of Medicine, and Paula S. Ramos is with the Departments of Medicine and Public Health Sciences, Medical University of South Carolina, Charleston. Dana Lee Olstad is with the Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada. Anna R. Kahkoska is with the Department of Nutrition, Laura V. Milko is with the Department of Genetics, and Megan C. Roberts is with the Eshelman School of Pharmacy, University of North Carolina, Chapel Hill. Yue Guan and Isabella Santangelo are with the Department of Behavioral, Social, and Health Education Sciences, Rollins School of Public Health, Emory University, Atlanta, GA. Julia Steinberg is with The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, Australia. Stephanie A. S. Staras is with the Department of Health Outcome and Biomedical Informatics, College of Medicine, and Institute for Child Health Policy, University of Florida, Gainesville. Crystal Y. Lumpkins is with the Department of Communication, Huntsman Cancer Institute, University of Utah, Salt Lake City. Erin Turbitt is with the Graduate School of Health, University of Technology Sydney, Ultimo, NSW, Australia. Alanna K. Rahm is with the Department of Genomic Health, Geisinger Medical Center, Danville, PA. Katherine W. Saylor is with the Department of Medical Ethics and Health Policy, Perelman School of Medicine, University of Pennsylvania, Philadelphia. Stephanie Best is with the Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
| |
Collapse
|
4
|
Dickey L, Gronowski B, Jones K, Rinaldi JB, Emery K, Clemens J, Gordon O, Vartanian K. Participation in genetic screening: testing different outreach methods across a diverse hospital system based patient population. Front Genet 2023; 14:1272931. [PMID: 37900185 PMCID: PMC10602775 DOI: 10.3389/fgene.2023.1272931] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Accepted: 09/29/2023] [Indexed: 10/31/2023] Open
Abstract
Introduction: Genomics has the potential to transform medicine by identifying genetic risk factors that predispose people to certain illnesses. Use of genetic screening is rapidly expanding and shifting towards screening all patients regardless of known risk factors, but research is limited on the success of broad population-level outreach for genetic testing and the effectiveness of different outreach methods across diverse populations. In this study, we tested the effectiveness of Digital Only (emailing and texting) and Brochure Plus Digital (mailed brochure, emailing, and texting) outreach to encourage a diverse patient population to participate in a large hospital system's whole genome sequencing program. Methods: Disproportionate stratified sampling was used to create a study population more demographically diverse than the eligible population and response rates were analyzed overall and by demographics to understand the effectiveness of different outreach strategies. Results: 7.5% of all eligible patients enrolled in the program. While approximately 70% of patients invited to complete genetic testing identified in their EHR as being Hispanic, Black or African America, Asian, or another non-White race, these patients generally enrolled at lower rates than the overall population. Other underrepresented groups had higher enrollment rates including people with Medicaid coverage (8.7%) and those residing in rural areas (10.6%). We found no significant difference in enrollment rates between our Digital-Only and our Brochure Plus Digital outreach approaches in the overall population, but enrollment rates were significantly higher for Asian patients and patients who resided in rural areas in the Brochure Plus Digital group. Across both outreach approaches, links provided in emails were most commonly used for enrollment. Discussion: Our study reveals expected enrollment rates for proactive outreach by a hospital system for genetic testing in a diverse population. As more hospital systems are adopting population-scale genetic testing, these findings can inform future outreach efforts to recruit patients for genetic testing including those patients traditionally underrepresented in genomics.
Collapse
Affiliation(s)
- Lindsay Dickey
- Center for Outcomes Research and Education, Portland, OR, United States
| | - Ben Gronowski
- Center for Outcomes Research and Education, Portland, OR, United States
| | - Kyle Jones
- Center for Outcomes Research and Education, Portland, OR, United States
| | - J. B. Rinaldi
- Center for Outcomes Research and Education, Portland, OR, United States
| | - Kate Emery
- Center for Clinical Genetics and Genomics for Providence Southern California, Burbank, CA, United States
| | - Jon Clemens
- Center for Clinical Genetics and Genomics for Providence Southern California, Burbank, CA, United States
| | - Ora Gordon
- Center for Clinical Genetics and Genomics for Providence Southern California, Burbank, CA, United States
| | - Keri Vartanian
- Center for Outcomes Research and Education, Portland, OR, United States
| |
Collapse
|
5
|
Cannon A, McMillan O, Kelley WV, East KM, Cochran ME, Miskell EL, Moss IP, Garner-Duckworth S, Redden DT, Might M, Barsh GS, Korf BR. Medical and psychosocial outcomes of state-funded population genomic screening. Clin Genet 2023; 104:434-442. [PMID: 37340305 PMCID: PMC11299714 DOI: 10.1111/cge.14394] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2023] [Revised: 06/06/2023] [Accepted: 06/09/2023] [Indexed: 06/22/2023]
Abstract
As the uptake of population screening expands, assessment of medical and psychosocial outcomes is needed. Through the Alabama Genomic Health Initiative (AGHI), a state-funded genomic research program, individuals received screening for pathogenic or likely pathogenic variants in 59 actionable genes via genotyping. Of the 3874 eligible participants that received screening results, 858 (22%) responded to an outcomes survey. The most commonly reported motivation for seeking testing through AGHI was contribution to genetic research (64%). Participants with positive results reported a higher median number of planned actions (median = 5) due to AGHI results as compared to negative results (median = 3). Interviews were conducted with survey participants with positive screening results. As determined by certified genetic counselors, 50% of interviewees took appropriate medical action based on their result. There were no negative or harmful actions taken. These findings indicate population genomic screening of an unselected adult population is feasible, is not harmful, and may have positive outcomes on participants now and in the future; however, further research is needed in order to assess clinical utility.
Collapse
Affiliation(s)
- Ashley Cannon
- Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Olivia McMillan
- School of Health Professions, University of Alabama at Birmingham, Birmingham, AL, USA
| | | | - Kelly M East
- HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA
| | | | - Edrika L. Miskell
- Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Irene P Moss
- Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | | | - David T Redden
- Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Matthew Might
- Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Gregory S Barsh
- HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA
| | - Bruce R Korf
- Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| |
Collapse
|
6
|
Kane NJ, Cohen ASA, Berrios C, Jones B, Pastinen T, Hoffman MA. Committing to genomic answers for all kids: Evaluating inequity in genomic research enrollment. Genet Med 2023; 25:100895. [PMID: 37194653 PMCID: PMC10524770 DOI: 10.1016/j.gim.2023.100895] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 05/08/2023] [Accepted: 05/10/2023] [Indexed: 05/18/2023] Open
Abstract
PURPOSE Persistent inequities in genomic medicine and research contribute to health disparities. This analysis uses a context-specific and equity-focused strategy to evaluate enrollment patterns for Genomic Answers for Kids (GA4K), a large, metropolitan-wide genomic study on children. METHODS Electronic health records for 2247 GA4K study participants were used to evaluate the distribution of individuals by demographics (race, ethnicity, and payor type) and location (residential address). Addresses were geocoded to produce point density and 3-digit zip code maps showing local and regional enrollment patterns. Health system reports and census data were used to compare participant characteristics with reference populations at different spatial scales. RESULTS Racial and ethnic minoritized and populations with low-income were underrepresented in the GA4K study cohort. Geographic variation demonstrates inequity in enrollment and participation among children from historically segregated and socially disadvantaged communities. CONCLUSION Our findings illustrate inequity in enrollment related to both GA4K study design and structural inequalities, which we suspect may exist for similar US-based studies. Our methods provide a scalable framework for continually evaluating and improving study design to ensure equitable participation in and benefits from genomic research and medicine. The use of high-resolution, place-based data represents a novel and practical means of identifying and characterizing inequities and targeting community engagement.
Collapse
|
7
|
Clayton EW, Smith ME, Anderson KC, Chung WK, Connolly JJ, Fullerton SM, McGowan ML, Peterson JF, Prows CA, Sabatello M, Holm IA. Studying the impact of translational genomic research: Lessons from eMERGE. Am J Hum Genet 2023; 110:1021-1033. [PMID: 37343562 PMCID: PMC10357472 DOI: 10.1016/j.ajhg.2023.05.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2023] [Revised: 05/22/2023] [Accepted: 05/23/2023] [Indexed: 06/23/2023] Open
Abstract
Two major goals of the Electronic Medical Record and Genomics (eMERGE) Network are to learn how best to return research results to patient/participants and the clinicians who care for them and also to assess the impact of placing these results in clinical care. Yet since its inception, the Network has confronted a host of challenges in achieving these goals, many of which had ethical, legal, or social implications (ELSIs) that required consideration. Here, we share impediments we encountered in recruiting participants, returning results, and assessing their impact, all of which affected our ability to achieve the goals of eMERGE, as well as the steps we took to attempt to address these obstacles. We divide the domains in which we experienced challenges into four broad categories: (1) study design, including recruitment of more diverse groups; (2) consent; (3) returning results to participants and their health care providers (HCPs); and (4) assessment of follow-up care of participants and measuring the impact of research on participants and their families. Since most phases of eMERGE have included children as well as adults, we also address the particular ELSI posed by including pediatric populations in this research. We make specific suggestions for improving translational genomic research to ensure that future projects can effectively return results and assess their impact on patient/participants and providers if the goals of genomic-informed medicine are to be achieved.
Collapse
Affiliation(s)
- Ellen Wright Clayton
- Center for Biomedical Ethics and Society, Departments of Pediatrics and Health Policy, Vanderbilt University Medical Center, Nashville, TN 37203, USA.
| | - Maureen E Smith
- Department of Medicine, Center for Genetic Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Katherine C Anderson
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Wendy K Chung
- Departments of Pediatrics and Medicine, Columbia University, New York, NY 10032, USA
| | - John J Connolly
- Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA
| | - Stephanie M Fullerton
- Department of Bioethics & Humanities, University of Washington School of Medicine, Seattle, WA 98195, USA
| | - Michelle L McGowan
- Biomedical Ethics Research Program, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA; Department of Women's, Gender, and Sexuality Studies, University of Cincinnati, Cincinnati, OH 45221, USA
| | - Josh F Peterson
- Center for Precision Medicine, Department of Biomedical Informatics, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37203, USA
| | - Cynthia A Prows
- Divisions of Human Genetics and Patient Services, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA
| | - Maya Sabatello
- Center for Precision Medicine & Genomics, Department of Medicine, and Division of Ethics, Department of Medical Humanities & Ethics Columbia University Vagelos College of Physicians and Surgeons, NY, NY 10032, USA
| | - Ingrid A Holm
- Division of Genetics and Genomics, Boston Children's Hospital; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA
| |
Collapse
|
8
|
Parker LL, Bonner CM, Sobol RW, Arrieta MI. Co-creation and engagement in a DNA integrity cohort study. J Clin Transl Sci 2023; 7:e122. [PMID: 37313377 PMCID: PMC10260344 DOI: 10.1017/cts.2023.556] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2023] [Revised: 05/03/2023] [Accepted: 05/10/2023] [Indexed: 06/15/2023] Open
Abstract
Introduction The partnership between a research community engagement team (CE Team) and a community advisory board (CAB) formed the basis for bidirectional communication in developing resources for participant recruitment in a DNA integrity study. Engaging with a minoritized community, this partnership focused on respect, accessibility, and expanded engagement. Methods A ten-member CAB, working in two groups defined by meeting time convenience, provided insight and feedback to the CE Team in the creation of recruitment and consent materials, via an iterative design process in which one CAB group reviewed and enhanced materials, and the second group tested and refined them further. The continuous analysis of CE Team notes from CAB meetings captured information needed both for materials refinement and implementation of CAB-suggested activities. Results The partnership resulted in the co-creation of recruitment and consent materials that facilitated the enrollment of 191 individuals into the study. The CAB encouraged and assisted in expanded engagement inclusive of community leaders. This broader engagement provided information about the DNA integrity study to community decision-makers as well as responded to questions and concerns about the research. The bidirectional communication between the CAB and the CE Team encouraged the researchers to consider topics and research interests related to the current study but also responsive to community concerns. Conclusions The CAB helped the CE Team develop a better understanding of the language of partnership and respect. In this way, the partnership opened doors for expanded community engagement and effective communication with potential study participants.
Collapse
Affiliation(s)
- L. Lynette Parker
- Center for Healthy Communities, Frederick P. Whiddon College of Medicine, University of South Alabama, Mobile, AL, USA
| | - Chantel M. Bonner
- Center for Healthy Communities, Frederick P. Whiddon College of Medicine, University of South Alabama, Mobile, AL, USA
| | - Robert W. Sobol
- Mitchell Cancer Institute, University of South Alabama, Mobile, AL, USA
- Department of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL, USA
- Department of Pathology and Laboratory Medicine, Warren Alpert Medical School & Legorreta Cancer Center, Brown University, Providence, RI, USA
| | - Martha I. Arrieta
- Center for Healthy Communities, Frederick P. Whiddon College of Medicine, University of South Alabama, Mobile, AL, USA
| |
Collapse
|
9
|
Rao ND, Kaganovsky J, Malouf EA, Coe S, Huey J, Tsinajinne D, Hassan S, King KM, Fullerton SM, Chen AT, Shirts BH. Diagnostic yield of genetic screening in a diverse, community-ascertained cohort. Genome Med 2023; 15:26. [PMID: 37069702 PMCID: PMC10111761 DOI: 10.1186/s13073-023-01174-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2022] [Accepted: 03/16/2023] [Indexed: 04/19/2023] Open
Abstract
BACKGROUND Population screening for genetic risk of adult-onset preventable conditions has been proposed as an attractive public health intervention. Screening unselected individuals can identify many individuals who will not be identified through current genetic testing guidelines. METHODS We sought to evaluate enrollment in and diagnostic yield of population genetic screening in a resource-limited setting among a diverse population. We developed a low-cost, short-read next-generation sequencing panel of 25 genes that had 98.4% sensitivity and 99.98% specificity compared to diagnostic panels. We used email invitations to recruit a diverse cohort of patients in the University of Washington Medical Center system unselected for personal or family history of hereditary disease. Participants were sent a saliva collection kit in the mail with instructions on kit use and return. Results were returned using a secure online portal. Enrollment and diagnostic yield were assessed overall and across race and ethnicity groups. RESULTS Overall, 40,857 people were invited and 2889 (7.1%) enrolled. Enrollment varied across race and ethnicity groups, with the lowest enrollment among African American individuals (3.3%) and the highest among Multiracial or Other Race individuals (13.0%). Of 2864 enrollees who received screening results, 106 actionable variants were identified in 103 individuals (3.6%). Of those who screened positive, 30.1% already knew about their results from prior genetic testing. The diagnostic yield was 74 new, actionable genetic findings (2.6%). The addition of more recently identified cancer risk genes increased the diagnostic yield of screening. CONCLUSIONS Population screening can identify additional individuals that could benefit from prevention, but challenges in recruitment and sample collection will reduce actual enrollment and yield. These challenges should not be overlooked in intervention planning or in cost and benefit analysis.
Collapse
Affiliation(s)
- Nandana D Rao
- Institute for Public Health Genetics, University of Washington, Seattle, WA, USA
| | - Jailanie Kaganovsky
- Department of Laboratory Medicine and Pathology, University of Washington, Rm NW120, Box 357110 1959 NE Pacific Street, WA, 98195, Seattle, USA
| | - Emily A Malouf
- Department of Laboratory Medicine and Pathology, University of Washington, Rm NW120, Box 357110 1959 NE Pacific Street, WA, 98195, Seattle, USA
| | - Sandy Coe
- Department of Laboratory Medicine and Pathology, University of Washington, Rm NW120, Box 357110 1959 NE Pacific Street, WA, 98195, Seattle, USA
| | - Jennifer Huey
- Department of Laboratory Medicine and Pathology, University of Washington, Rm NW120, Box 357110 1959 NE Pacific Street, WA, 98195, Seattle, USA
| | - Darwin Tsinajinne
- Department of Laboratory Medicine and Pathology, University of Washington, Rm NW120, Box 357110 1959 NE Pacific Street, WA, 98195, Seattle, USA
| | - Sajida Hassan
- Department of Laboratory Medicine and Pathology, University of Washington, Rm NW120, Box 357110 1959 NE Pacific Street, WA, 98195, Seattle, USA
| | - Kristine M King
- Institute for Public Health Genetics, University of Washington, Seattle, WA, USA
| | - Stephanie M Fullerton
- Department of Bioethics & Humanities, University of Washington School of Medicine, Seattle, WA, USA
| | - Annie T Chen
- Department of Biomedical Informatics and Medical Education, University of Washington, Seattle, WA, USA
| | - Brian H Shirts
- Department of Laboratory Medicine and Pathology, University of Washington, Rm NW120, Box 357110 1959 NE Pacific Street, WA, 98195, Seattle, USA.
- Brotman Baty Institute, Seattle, WA, USA.
| |
Collapse
|
10
|
Shi JJ, Lei X, Chen YS, Chavez-MacGregor M, Bloom E, Schlembach P, Shaitelman SF, Buchholz TA, Kaiser K, Ku K, Smith BD, Smith GL. Socioeconomic Barriers to Randomized Clinical Trial Retention in Patients Treated With Adjuvant Radiation for Early-Stage Breast Cancer. Int J Radiat Oncol Biol Phys 2023; 116:122-131. [PMID: 36724858 DOI: 10.1016/j.ijrobp.2023.01.037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Revised: 01/19/2023] [Accepted: 01/23/2023] [Indexed: 01/30/2023]
Abstract
PURPOSE Socioeconomic barriers contribute to breast cancer clinical trial enrollment disparities. We sought to identify whether socioeconomic disadvantage also is associated with decreased trial retention. METHODS AND MATERIALS We performed a secondary analysis of 253 (of 287) patients enrolled in a randomized phase 3 trial of conventionally fractionated versus hypofractionated whole-breast irradiation. The outcome of trial retention versus dropout was defined primarily based on whether the patient completed breast cosmesis outcomes assessment at 3-year follow-up, and secondarily, at 5-year follow-up. Associations of retention with severity of socioeconomic disadvantage, quantified by patients' home neighborhood area deprivation index (ADI) rank (1 [least] to 100 [most deprivation]), were tested using the Kruskal-Wallis test and multivariate logistic regression. Associations of retention with patients' use of social resource assistance were analyzed using the χ2 test. RESULTS In total, 21.7% (n = 55) of patients dropped out by 3 years and 36.7% (n = 92) by 5 years. Median ADI was 36.5 (interquartile range, 22-57) for retained and 46.0 (interquartile range, 29-60) for dropout patients. Dropout was associated with more severe socioeconomic deprivation (ADI ≥45 vs <45) at 3 years (odds ratio, 3.63; 95% confidence interval, 1.62-8.15; P = .002) and 5 years (odds ratio, 2.55; 95% confidence interval, 1.37-4.76; P = .003). While on study, patients who ultimately dropped out were more likely to require resource assistance for practical (transportation, housing, financial) than psychological needs (distress, grief) or advance care planning (P = .03). CONCLUSIONS In this study, ADI was associated with disparities in clinical trial retention of patients with breast cancer receiving adjuvant radiation treatment. Results suggest that developing multidimensional interventions that extend beyond routine social determinants needs screening are needed, not only to enhance initial clinical trial access and enrollment but also to enable robust long-term retention of socioeconomically disadvantaged patients and improve the validity and generalizability of reported long-term trial clinical and patient-reported outcomes.
Collapse
Affiliation(s)
- Julia J Shi
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Xiudong Lei
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | | | - Elizabeth Bloom
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | | | | | - Kelsey Kaiser
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Kimberly Ku
- University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | - Grace L Smith
- University of Texas MD Anderson Cancer Center, Houston, Texas.
| |
Collapse
|
11
|
Eadon MT, Cavanaugh KL, Orlando LA, Christian D, Chakraborty H, Steen-Burrell KA, Merrill P, Seo J, Hauser D, Singh R, Beasley CM, Fuloria J, Kitzman H, Parker AS, Ramos M, Ong HH, Elwood EN, Lynch SE, Clermont S, Cicali EJ, Starostik P, Pratt VM, Nguyen KA, Rosenman MB, Calman NS, Robinson M, Nadkarni GN, Madden EB, Kucher N, Volpi S, Dexter PR, Skaar TC, Johnson JA, Cooper-DeHoff RM, Horowitz CR. Design and rationale of GUARDD-US: A pragmatic, randomized trial of genetic testing for APOL1 and pharmacogenomic predictors of antihypertensive efficacy in patients with hypertension. Contemp Clin Trials 2022; 119:106813. [PMID: 35660539 PMCID: PMC9928488 DOI: 10.1016/j.cct.2022.106813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2022] [Revised: 05/25/2022] [Accepted: 05/30/2022] [Indexed: 11/28/2022]
Abstract
RATIONALE AND OBJECTIVE APOL1 risk alleles are associated with increased cardiovascular and chronic kidney disease (CKD) risk. It is unknown whether knowledge of APOL1 risk status motivates patients and providers to attain recommended blood pressure (BP) targets to reduce cardiovascular disease. STUDY DESIGN Multicenter, pragmatic, randomized controlled clinical trial. SETTING AND PARTICIPANTS 6650 individuals with African ancestry and hypertension from 13 health systems. INTERVENTION APOL1 genotyping with clinical decision support (CDS) results are returned to participants and providers immediately (intervention) or at 6 months (control). A subset of participants are re-randomized to pharmacogenomic testing for relevant antihypertensive medications (pharmacogenomic sub-study). CDS alerts encourage appropriate CKD screening and antihypertensive agent use. OUTCOMES Blood pressure and surveys are assessed at baseline, 3 and 6 months. The primary outcome is change in systolic BP from enrollment to 3 months in individuals with two APOL1 risk alleles. Secondary outcomes include new diagnoses of CKD, systolic blood pressure at 6 months, diastolic BP, and survey results. The pharmacogenomic sub-study will evaluate the relationship of pharmacogenomic genotype and change in systolic BP between baseline and 3 months. RESULTS To date, the trial has enrolled 3423 participants. CONCLUSIONS The effect of patient and provider knowledge of APOL1 genotype on systolic blood pressure has not been well-studied. GUARDD-US addresses whether blood pressure improves when patients and providers have this information. GUARDD-US provides a CDS framework for primary care and specialty clinics to incorporate APOL1 genetic risk and pharmacogenomic prescribing in the electronic health record. TRIAL REGISTRATION ClinicalTrials.govNCT04191824.
Collapse
Affiliation(s)
- Michael T Eadon
- Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | | | - Lori A Orlando
- Duke University School of Medicine, Durham, NC 27720, USA
| | - David Christian
- Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Hrishikesh Chakraborty
- Duke University School of Medicine, Durham, NC 27720, USA; Duke Clinical Research Institute, Durham, NC 27720, USA
| | | | - Peter Merrill
- Duke Clinical Research Institute, Durham, NC 27720, USA
| | - Janet Seo
- Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Diane Hauser
- Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Institute for Family Health, New York, NY 10029, USA
| | - Rajbir Singh
- Meharry Medical College, Nashville, TN 37208, USA
| | - Cherry Maynor Beasley
- McKenzie-Elliott School of Nursing, University of North Carolina at Pembroke, Pembroke, NC 28372, USA
| | - Jyotsna Fuloria
- Office of Research, University Medical Center New Orleans, New Orleans, LA 70112, USA
| | - Heather Kitzman
- Baylor Scott & White Health, Baylor University, Robbins Institute for Health Policy & Leadership, Dallas, TX 75246, USA
| | - Alexander S Parker
- University of Florida College of Medicine - Jacksonville, Jacksonville, FL 32209, USA
| | - Michelle Ramos
- Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Henry H Ong
- Vanderbilt University Medical Center, Nashville, TN 37232, USA
| | - Erica N Elwood
- University of Florida, College of Pharmacy, Gainesville, FL 32610, USA
| | - Sheryl E Lynch
- Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Sabrina Clermont
- Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Emily J Cicali
- University of Florida, College of Pharmacy, Gainesville, FL 32610, USA
| | - Petr Starostik
- University of Florida, College of Medicine, Gainesville, FL 32610, USA
| | - Victoria M Pratt
- Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Khoa A Nguyen
- University of Florida, College of Pharmacy, Gainesville, FL 32610, USA
| | - Marc B Rosenman
- Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
| | - Neil S Calman
- Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Institute for Family Health, New York, NY 10029, USA
| | | | - Girish N Nadkarni
- Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Ebony B Madden
- Division of Genomic Medicine, National Human Genome Research Institute, Bethesda, MD 20892, USA
| | - Natalie Kucher
- Division of Genomic Medicine, National Human Genome Research Institute, Bethesda, MD 20892, USA
| | - Simona Volpi
- Division of Genomic Medicine, National Human Genome Research Institute, Bethesda, MD 20892, USA
| | - Paul R Dexter
- Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Todd C Skaar
- Indiana University School of Medicine, Indianapolis, IN 46202, USA
| | - Julie A Johnson
- University of Florida, College of Pharmacy, Gainesville, FL 32610, USA
| | | | - Carol R Horowitz
- Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
| |
Collapse
|
12
|
Shim JK, Bentz M, Vasquez E, Jeske M, Saperstein A, Fullerton SM, Foti N, McMahon C, Lee SSJ. Strategies of inclusion: The tradeoffs of pursuing "baked in" diversity through place-based recruitment. Soc Sci Med 2022; 306:115132. [PMID: 35728460 DOI: 10.1016/j.socscimed.2022.115132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2022] [Revised: 05/17/2022] [Accepted: 06/10/2022] [Indexed: 10/18/2022]
Abstract
US funding agencies have begun to institutionalize expectations that biomedical studies achieve defined thresholds for diversity among research participants, including in precision medicine research (PMR). In this paper, we examine how practices of recruitment have unfolded in the wake of these diversity mandates. We find that a very common approach to seeking diverse participants leverages understandings of spatial, geographic, and site diversity as proxies and access points for participant diversity. That is, PMR investigators recruit from a diverse sampling of geographic areas, neighborhoods, sites, and institutional settings as both opportunistic but also meaningful ways to "bake in" participant diversity. In this way, logics of geographic and institutional diversity shift the question from who to recruit, to where. However, despite seeing geographic and site diversity as social and scientific 'goods' in the abstract and as key to getting diverse participants, PMR teams told us that working with diverse sites was often difficult in practice due to constraints in funding, time, and personnel, and inadequate research infrastructures and capacity. Thus, the ways in which these geographic and institutional diversity strategies were implemented resulted ultimately in limiting the meaningful inclusion of populations and organizations that had not previously participated in biomedical research and reproduced the inclusion of institutions that are already represented. These prevailing assumptions about and practices of "baked-in" diversity in fact exacerbate and produce other forms of inequity, in research capacity and research representation. These findings underscore how structural inequities in research resources must be addressed for diversity to be achieved in both research sites and research participants.
Collapse
Affiliation(s)
- Janet K Shim
- Department of Social and Behavioral Sciences, University of California, San Francisco, USA.
| | - Michael Bentz
- Division of Ethics, Department of Medical Humanities and Ethics, Columbia University, USA
| | - Emily Vasquez
- Department of Sociology, University of Illinois-Chicago, USA
| | - Melanie Jeske
- Institute on the Formation of Knowledge, University of Chicago, USA
| | | | - Stephanie M Fullerton
- Department of Bioethics & Humanities, School of Medicine, University of Washington, USA
| | - Nicole Foti
- Department of Social and Behavioral Sciences, University of California, San Francisco, USA
| | - Caitlin McMahon
- Division of Ethics, Department of Medical Humanities and Ethics, Columbia University, USA
| | - Sandra Soo-Jin Lee
- Division of Ethics, Department of Medical Humanities and Ethics, Columbia University, USA
| |
Collapse
|
13
|
Bodicoat DH, Routen AC, Willis A, Ekezie W, Gillies C, Lawson C, Yates T, Zaccardi F, Davies MJ, Khunti K. Promoting inclusion in clinical trials-a rapid review of the literature and recommendations for action. Trials 2021; 22:880. [PMID: 34863265 PMCID: PMC8643184 DOI: 10.1186/s13063-021-05849-7] [Citation(s) in RCA: 63] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2021] [Accepted: 11/20/2021] [Indexed: 11/18/2022] Open
Abstract
Background Without inclusion of diverse research participants, it is challenging to understand how study findings will translate into the real world. Despite this, a lack of inclusion of those from under-served groups in research is a prevailing problem due to multi-faceted barriers acting at multiple levels. Therefore, we rapidly reviewed international published literature, in relation to clinical trials, on barriers relating to inclusion, and evidence of approaches that are effective in overcoming these. Methods A rapid literature review was conducted searching PubMed for peer-reviewed articles that discussed barriers to inclusion or strategies to improve inclusion in clinical trial research published between 2010 and 2021. Grey literature articles were excluded. Results Seventy-two eligible articles were included. The main barriers identified were language and communication, lack of trust, access to trials, eligibility criteria, attitudes and beliefs, lack of knowledge around clinical trials, and logistical and practical issues. In relation to evidence-based strategies and enablers, two key themes arose: [1] a multi-faceted approach is essential [2]; no single strategy was universally effective either within or between trials. The key evidence-based strategies identified were cultural competency training, community partnerships, personalised approach, multilingual materials and staff, communication-specific strategies, increasing understanding and trust, and tackling logistical barriers. Conclusions Many of the barriers relating to inclusion are the same as those that impact trial design and healthcare delivery generally. However, the presentation of these barriers among different under-served groups may be unique to each population’s particular circumstances, background, and needs. Based on the literature, we make 15 recommendations that, if implemented, may help improve inclusion within clinical trials and clinical research more generally. The three main recommendations include improving cultural competency and sensitivity of all clinical trial staff through training and ongoing personal development, the need to establish a diverse community advisory panel for ongoing input into the research process, and increasing recruitment of staff from under-served groups. Implementation of these recommendations may help improve representation of under-served groups in clinical trials which would improve the external validity of associated findings. Supplementary Information The online version contains supplementary material available at 10.1186/s13063-021-05849-7.
Collapse
Affiliation(s)
| | - Ash C Routen
- Centre for Ethnic Health Research, University of Leicester, Leicester General Hospital, Leicester, UK.,Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
| | - Andrew Willis
- Centre for Ethnic Health Research, University of Leicester, Leicester General Hospital, Leicester, UK.,Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
| | - Winifred Ekezie
- Centre for Ethnic Health Research, University of Leicester, Leicester General Hospital, Leicester, UK.,Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
| | - Clare Gillies
- Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
| | - Claire Lawson
- Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
| | - Thomas Yates
- Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.,NIHR Leicester Biomedical Research Centre, Leicester General Hospital, Leicester, UK
| | - Francesco Zaccardi
- Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK
| | - Melanie J Davies
- Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.,NIHR Leicester Biomedical Research Centre, Leicester General Hospital, Leicester, UK.,Leicester Diabetes Centre, University Hospitals of Leicester NHS Trust, Leicester, UK
| | - Kamlesh Khunti
- Centre for Ethnic Health Research, University of Leicester, Leicester General Hospital, Leicester, UK. .,Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK. .,NIHR Leicester Biomedical Research Centre, Leicester General Hospital, Leicester, UK. .,Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.
| |
Collapse
|
14
|
Gutierrez AM, Robinson JO, Outram SM, Smith HS, Kraft SA, Donohue KE, Biesecker BB, Brothers KB, Chen F, Hailu B, Hindorff LA, Hoban H, Hsu RL, Knight SJ, Koenig BA, Lewis KL, Lich KH, O’Daniel JM, Okuyama S, Tomlinson GE, Waltz M, Wilfond BS, Ackerman SL, Majumder MA. Examining access to care in clinical genomic research and medicine: Experiences from the CSER Consortium. J Clin Transl Sci 2021; 5:e193. [PMID: 34888063 PMCID: PMC8634302 DOI: 10.1017/cts.2021.855] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2021] [Revised: 08/30/2021] [Accepted: 09/06/2021] [Indexed: 12/12/2022] Open
Abstract
INTRODUCTION Ensuring equitable access to health care is a widely agreed-upon goal in medicine, yet access to care is a multidimensional concept that is difficult to measure. Although frameworks exist to evaluate access to care generally, the concept of "access to genomic medicine" is largely unexplored and a clear framework for studying and addressing major dimensions is lacking. METHODS Comprised of seven clinical genomic research projects, the Clinical Sequencing Evidence-Generating Research consortium (CSER) presented opportunities to examine access to genomic medicine across diverse contexts. CSER emphasized engaging historically underrepresented and/or underserved populations. We used descriptive analysis of CSER participant survey data and qualitative case studies to explore anticipated and encountered access barriers and interventions to address them. RESULTS CSER's enrolled population was largely lower income and racially and ethnically diverse, with many Spanish-preferring individuals. In surveys, less than a fifth (18.7%) of participants reported experiencing barriers to care. However, CSER project case studies revealed a more nuanced picture that highlighted the blurred boundary between access to genomic research and clinical care. Drawing on insights from CSER, we build on an existing framework to characterize the concept and dimensions of access to genomic medicine along with associated measures and improvement strategies. CONCLUSIONS Our findings support adopting a broad conceptualization of access to care encompassing multiple dimensions, using mixed methods to study access issues, and investing in innovative improvement strategies. This conceptualization may inform clinical translation of other cutting-edge technologies and contribute to the promotion of equitable, effective, and efficient access to genomic medicine.
Collapse
Affiliation(s)
- Amanda M. Gutierrez
- Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA
| | - Jill O. Robinson
- Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA
| | - Simon M. Outram
- Program in Bioethics, University of California, San Francisco, San Francisco, CA, USA
| | - Hadley S. Smith
- Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA
| | - Stephanie A. Kraft
- Treuman Katz Center for Pediatric Bioethics, Seattle Children’s Research Institute, Seattle, WA, USA
- Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
| | - Katherine E. Donohue
- Institute for Genomic Health, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Barbara B. Biesecker
- RTI International, GenOmics, BiOinformatics and Translational Science, Washington DC, USA
| | - Kyle B. Brothers
- Department of Pediatrics, University of Louisville, Louisville, KY, USA
| | - Flavia Chen
- Program in Bioethics, University of California, San Francisco, San Francisco, CA, USA
- Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA
| | - Benyam Hailu
- National Institute of Minority Health and Health Disparities, National Institutes of Health, Bethesda, MD, USA
| | - Lucia A. Hindorff
- Division of Genomic Medicine, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Hannah Hoban
- Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, USA
| | - Rebecca L. Hsu
- Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA
| | - Sara J. Knight
- Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA
| | | | - Katie L. Lewis
- National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA
| | - Kristen Hassmiller Lich
- Department of Health Policy and Management, University of North Carolina Chapel Hill, Chapel Hill, NC, USA
| | - Julianne M. O’Daniel
- Department of Genetics, University of North Carolina Chapel Hill, Chapel Hill, NC, USA
| | - Sonia Okuyama
- Division of Hematology-Oncology, Denver Health and Hospital Authority, Denver, CO, USA
| | - Gail E. Tomlinson
- Division of Hematology-Oncology, Department of Pediatrics, University of Texas Health Science Center San Antonio, San Antonio, TX, USA
- Greehey Children’s Cancer Research Institute, University of Texas Health Science Center San Antonio, San Antonio, TX, USA
| | - Margaret Waltz
- Department of Social Medicine, University of North Carolina Chapel Hill, Chapel Hill, NC, USA
| | - Benjamin S. Wilfond
- Treuman Katz Center for Pediatric Bioethics, Seattle Children’s Research Institute, Seattle, WA, USA
- Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
| | - Sara L. Ackerman
- Department of Social and Behavioral Sciences, University of California, San Francisco, San Francisco, CA, USA
| | - Mary A. Majumder
- Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, USA
| |
Collapse
|
15
|
Massett HA, Mitchell AK, Alley L, Simoneau E, Burke P, Han SH, Gallop-Goodman G, McGowan M. Facilitators, Challenges, and Messaging Strategies for Hispanic/Latino Populations Participating in Alzheimer's Disease and Related Dementias Clinical Research: A Literature Review. J Alzheimers Dis 2021; 82:107-127. [PMID: 33998537 DOI: 10.3233/jad-201463] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) disproportionally affect Hispanic and Latino populations, yet Hispanics/Latinos are substantially underrepresented in AD/ADRD clinical research. Diverse inclusion in trials is an ethical and scientific imperative, as underrepresentation reduces the ability to generalize study findings and treatments across populations most affected by a disease. This paper presents findings from a narrative literature review (N = 210) of the current landscape of Hispanic/Latino participation in clinical research, including the challenges, facilitators, and communication channels to conduct culturally appropriate outreach efforts to increase awareness and participation of Hispanics/Latinos in AD/ADRD clinical research studies. Many challenges identified were systemic in nature: lack of culturally relevant resources; staffing that does not represent participants' cultures/language; eligibility criteria that disproportionately excludes Hispanics/Latinos; and too few studies available in Hispanic/Latino communities. The paper also details facilitators and messaging strategies to improve engagement and interest among Hispanics/Latinos in AD/ADRD research, starting with approaches that recognize and address the heterogeneity of the Hispanic/Latino ethnicity, and then, tailor outreach activities and programs to address their diverse needs and circumstances. The needs identified in this article represent longstanding failures to improve engagement and interest among Hispanics/Latinos in AD/ADRD research; we discuss how the field can move forward learning from the experiences of the COVID-19 pandemic.
Collapse
Affiliation(s)
- Holly A Massett
- Division of Extramural Activities, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | | | | | | | | | - Sae H Han
- Kelly Government, Kelly Services, Inc., Rockville, MD, USA
| | - Gerda Gallop-Goodman
- Office of Communications and Public Liaison, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| | - Melissa McGowan
- Office of Communications and Public Liaison, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
| |
Collapse
|
16
|
Sperber NR, Dong OM, Roberts MC, Dexter P, Elsey AR, Ginsburg GS, Horowitz CR, Johnson JA, Levy KD, Ong H, Peterson JF, Pollin TI, Rakhra-Burris T, Ramos MA, Skaar T, Orlando LA. Strategies to Integrate Genomic Medicine into Clinical Care: Evidence from the IGNITE Network. J Pers Med 2021; 11:647. [PMID: 34357114 PMCID: PMC8306482 DOI: 10.3390/jpm11070647] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Revised: 06/29/2021] [Accepted: 07/02/2021] [Indexed: 11/16/2022] Open
Abstract
The complexity of genomic medicine can be streamlined by implementing some form of clinical decision support (CDS) to guide clinicians in how to use and interpret personalized data; however, it is not yet clear which strategies are best suited for this purpose. In this study, we used implementation science to identify common strategies for applying provider-based CDS interventions across six genomic medicine clinical research projects funded by an NIH consortium. Each project's strategies were elicited via a structured survey derived from a typology of implementation strategies, the Expert Recommendations for Implementing Change (ERIC), and follow-up interviews guided by both implementation strategy reporting criteria and a planning framework, RE-AIM, to obtain more detail about implementation strategies and desired outcomes. We found that, on average, the three pharmacogenomics implementation projects used more strategies than the disease-focused projects. Overall, projects had four implementation strategies in common; however, operationalization of each differed in accordance with each study's implementation outcomes. These four common strategies may be important for precision medicine program implementation, and pharmacogenomics may require more integration into clinical care. Understanding how and why these strategies were successfully employed could be useful for others implementing genomic or precision medicine programs in different contexts.
Collapse
Affiliation(s)
- Nina R. Sperber
- Duke Department of Population Health Sciences, Duke University School of Medicine, Durham, NC 27701, USA
- Durham VA Health Care System, Durham, NC 27705, USA
- Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, Durham, NC 27708, USA; (O.M.D.); (G.S.G.); (T.R.-B.); (L.A.O.)
| | - Olivia M. Dong
- Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, Durham, NC 27708, USA; (O.M.D.); (G.S.G.); (T.R.-B.); (L.A.O.)
| | - Megan C. Roberts
- Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA;
| | - Paul Dexter
- Regenstrief Institute, Indianapolis, Indiana University School of Medicine and Clem McDonald Center for Biomedical Informatics, Indianapolis, IN 46202, USA;
| | - Amanda R. Elsey
- Center for Pharmacogenomics and Precision Medicine, Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL 32610, USA; (A.R.E.); (J.A.J.)
| | - Geoffrey S. Ginsburg
- Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, Durham, NC 27708, USA; (O.M.D.); (G.S.G.); (T.R.-B.); (L.A.O.)
| | - Carol R. Horowitz
- Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA;
| | - Julie A. Johnson
- Center for Pharmacogenomics and Precision Medicine, Department of Pharmacotherapy and Translational Research, University of Florida, Gainesville, FL 32610, USA; (A.R.E.); (J.A.J.)
| | - Kenneth D. Levy
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, 950 W. Walnut Street, Indianapolis, IN 46202, USA; (K.D.L.); (T.S.)
| | - Henry Ong
- Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; (H.O.); (J.F.P.)
| | - Josh F. Peterson
- Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN 37232, USA; (H.O.); (J.F.P.)
| | - Toni I. Pollin
- Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA;
| | - Tejinder Rakhra-Burris
- Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, Durham, NC 27708, USA; (O.M.D.); (G.S.G.); (T.R.-B.); (L.A.O.)
| | - Michelle A. Ramos
- Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA;
| | - Todd Skaar
- Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, 950 W. Walnut Street, Indianapolis, IN 46202, USA; (K.D.L.); (T.S.)
| | - Lori A. Orlando
- Center for Applied Genomics & Precision Medicine, Duke University School of Medicine, Durham, NC 27708, USA; (O.M.D.); (G.S.G.); (T.R.-B.); (L.A.O.)
| |
Collapse
|
17
|
Raymond MB, Cooper KE, Parker LS, Bonham VL. Practices and Attitudes toward Returning Genomic Research Results to Low-Resource Research Participants. Public Health Genomics 2021; 24:241-252. [PMID: 34229325 DOI: 10.1159/000516782] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2020] [Accepted: 04/21/2021] [Indexed: 11/19/2022] Open
Abstract
INTRODUCTION Many research programs are challenged to accommodate low-resource research participants' (LRRP) ancillary care needs when returning genomic research results. We define LRRP as those who are low income, uninsured, underinsured, or facing barriers to act upon the results returned. This study evaluates current policies and practices surrounding return of results (RoR) to LRRP, as well as the attitudes of investigators toward providing ancillary care to LRRP. METHODS A semi-structured interview study was conducted with representatives of 35 genomic research programs nationwide. Eligible programs were returning, or planning to return, medically actionable genomic results to participants. RESULTS Three content categories emerged from this study, including: (1) RoR structures, (2) barriers to RoR to LRRP, and (3) solutions to meet community and LRRP needs. Three major structures of RoR emerged: (1) RoR Embedded in Clinical Care, (2) RoR Independent of Clinical Care, and (3) Reliance on Clinical Partnerships to Facilitate RoR. Inadequacy of program resources to address the needs of LRRP was commonly considered a significant obstacle. The attitudes and views of informants regarding responsibility to provide ancillary care for LRRP receiving genomic results were highly varied. Some informants believed that genomic sequencing and testing was not a priority for LRRP because of other pressing issues in their lives, such as housing and food insecurity. Research programs differ regarding whether clinical and social support for LRRP is considered within the purview of the research team. Some programs instituted accommodations for LRRP, including social work referral and insurance enrollment assistance. CONCLUSION Support to access downstream treatment is not readily available for LRRP in many genomic research programs. Development of best practices and policies for managing RoR to LRRP is needed.
Collapse
Affiliation(s)
- Megan B Raymond
- Social and Behavioral Research Branch, National Human Genome Research, National Institutes of Health, Bethesda, Maryland, USA.,University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
| | - Kayla E Cooper
- Social and Behavioral Research Branch, National Human Genome Research, National Institutes of Health, Bethesda, Maryland, USA
| | - Lisa S Parker
- University of Pittsburgh, Center for Bioethics & Health Law, Human Genetics, Graduate School of Public Health, Pittsburgh, Pennsylvania, USA
| | - Vence L Bonham
- Social and Behavioral Research Branch, National Human Genome Research, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
18
|
Stanciu J, Tariman JD. Liquid Biopsy: A Tool for the Diagnostic and Prognostic Evaluation of Cancers. Clin J Oncol Nurs 2021; 24:19-21. [PMID: 31961840 DOI: 10.1188/20.cjon.19-21] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Liquid biopsy is defined as the process of obtaining material for pathologic examination and analysis from body fluids. Liquid biopsy has been intensively researched for its clinical application in patients with solid malignancies, including melanoma and colon, breast, and lung cancers. This will become a standard and routine tool for the diagnostic and prognostic evaluation of all cancer types. This article provides an overview of liquid biopsy, its uses in cancer management, and its implications for nursing practice.
Collapse
|
19
|
Perni S, Hong K, Hong TS, Nipp RD. Toward a Science of Personalized Informed Consent in Cancer Clinical Trials. JCO Oncol Pract 2021; 17:655-661. [PMID: 33974444 DOI: 10.1200/op.20.00975] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Subha Perni
- Harvard Radiation Oncology Program, Massachusetts General Hospital and Brigham and Women's Hospital/Dana-Farber Cancer Institute, Boston, MA.,Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA
| | - Kessely Hong
- Harvard Kennedy School, Harvard University, Boston, MA
| | - Theodore S Hong
- Department of Radiation Oncology, Massachusetts General Hospital Cancer Center, Boston, MA
| | - Ryan D Nipp
- Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, MA
| |
Collapse
|
20
|
Strategic vision for improving human health at The Forefront of Genomics. Nature 2020; 586:683-692. [PMID: 33116284 DOI: 10.1038/s41586-020-2817-4] [Citation(s) in RCA: 168] [Impact Index Per Article: 42.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 09/04/2020] [Indexed: 12/20/2022]
Abstract
Starting with the launch of the Human Genome Project three decades ago, and continuing after its completion in 2003, genomics has progressively come to have a central and catalytic role in basic and translational research. In addition, studies increasingly demonstrate how genomic information can be effectively used in clinical care. In the future, the anticipated advances in technology development, biological insights, and clinical applications (among others) will lead to more widespread integration of genomics into almost all areas of biomedical research, the adoption of genomics into mainstream medical and public-health practices, and an increasing relevance of genomics for everyday life. On behalf of the research community, the National Human Genome Research Institute recently completed a multi-year process of strategic engagement to identify future research priorities and opportunities in human genomics, with an emphasis on health applications. Here we describe the highest-priority elements envisioned for the cutting-edge of human genomics going forward-that is, at 'The Forefront of Genomics'.
Collapse
|
21
|
Shah-Williams E, Levy KD, Zang Y, Holmes AM, Stoughton C, Dexter P, Skaar TC. Enrollment of Diverse Populations in the INGENIOUS Pharmacogenetics Clinical Trial. Front Genet 2020; 11:571. [PMID: 32670350 PMCID: PMC7330082 DOI: 10.3389/fgene.2020.00571] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2019] [Accepted: 05/11/2020] [Indexed: 12/15/2022] Open
Abstract
Recruitment of diverse populations and subjects living in Medically Underserved Areas and Populations (MUA/P's) into clinical trials is a considerable challenge. Likewise, representation of African-Americans in pharmacogenetic trials is often inadequate, but critical for identifying genetic variation within and between populations. To identify enrollment patterns and variables that predict enrollment in a diverse underserved population, we analyzed data from the INGENIOUS (Indiana GENomics Implementation and Opportunity for the UnderServed), pharmacogenomics implementation clinical trial conducted at a community hospital for underserved subjects (Safety net hospital), and a statewide healthcare system (Academic hospital). We used a logistic regression model to identify patient variables that predicted successful enrollment after subjects were contacted and evaluated the reasons that clinical trial eligible subjects refused enrollment. In both healthcare systems, African-Americans were less likely to refuse the study than non-Hispanic Whites (Safety net, OR = 0.68, and p < 0.002; Academic hospital, OR = 0.64, and p < 0.001). At the Safety net hospital, other minorities were more likely to refuse the study than non-Hispanic Whites (OR = 1.58, p < 0.04). The odds of refusing the study once contacted increased with patient age (Safety net hospital, OR = 1.02, p < 0.001, Academic hospital, OR = 1.02, and p < 0.001). At the Academic hospital, females were less likely to refuse the study than males (OR = 0.81, p = 0.01) and those not living in MUA/P's were less likely to refuse the study than those living in MUA/P's (OR = 0.81, p = 0.007). The most frequent barriers to enrollment included not being interested, being too busy, transportation, and illness. A lack of trust was reported less frequently. In conclusion, African-Americans can be readily recruited to pharmacogenetic clinical trials once contact has been successfully initiated. However, health care initiatives and increased recruitment efforts of subjects living in MUA/Ps are needed. Enrollment could be further enhanced by improving research awareness and knowledge of clinical trials, reducing time needed for participation, and compensating for travel.
Collapse
Affiliation(s)
- Ebony Shah-Williams
- Department of Medical and Molecular Genetics, Indiana University, Indianapolis, IN, United States
| | - Kenneth D. Levy
- Department of Medicine, Indiana University, Indianapolis, IN, United States
| | - Yong Zang
- Department of Biostatistics, Indiana University, Indianapolis, IN, United States
| | - Ann M. Holmes
- Department of Health Policy and Management, Fairbanks School of Public Health, Indiana University–Purdue University Indianapolis, Indianapolis, IN, United States
| | - Christa Stoughton
- Department of Urology, Indiana University Hospital, Indianapolis, IN, United States
| | - Paul Dexter
- Department of Medicine, Indiana University, Indianapolis, IN, United States
- Regenstrief Institute for Health Care, Indianapolis, IN, United States
| | - Todd C. Skaar
- Department of Medicine, Indiana University, Indianapolis, IN, United States
| |
Collapse
|
22
|
Genetic testing and results disclosure in diverse populations: what does it take? Genet Med 2020; 22:1461-1463. [PMID: 32565545 DOI: 10.1038/s41436-020-0874-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2020] [Accepted: 06/09/2020] [Indexed: 11/08/2022] Open
|
23
|
Schoenthaler A, Fei K, Ramos MA, Richardson LD, Ogedegbe G, Horowitz CR. Comprehensive examination of the multilevel adverse risk and protective factors for cardiovascular disease among hypertensive African Americans. J Clin Hypertens (Greenwich) 2019; 21:794-803. [PMID: 31125186 DOI: 10.1111/jch.13560] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2019] [Revised: 04/24/2019] [Accepted: 05/05/2019] [Indexed: 12/25/2022]
Abstract
This paper describes the multilevel factors that contribute to hypertension disparities in 2052 hypertensive African Americans (mean age 52.9 ± 9.9 years; 66.3% female) who participated in a clinical trial. At the family level, participants reported average levels of life chaos and high social support. However, at the individual level, participants exhibited several adverse clinical and behavioral factors including poor blood pressure control (45% of population), obesity (61%), medication non-adherence (48%), smoking (32%), physical inactivity (45%), and poor diet (71%). While participants rated their provider as trustworthy, they reported high levels of discrimination in the health care system. Finally, community-level data indicate that participants reside in areas characterized by poor socio-economic and neighborhood conditions (eg, segregation). In the context of our trial, hypertensive African Americans exhibited several adverse risks and protective factors at multiple levels of influence. Future research should evaluate the impact of these factors on cardiovascular outcomes using a longitudinal design.
Collapse
Affiliation(s)
- Antoinette Schoenthaler
- Department of Population Health, Center for Healthful Behavior Change, New York University School of Medicine, New York, New York
| | - Kezhen Fei
- Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.,Center for Health Equity and Community Engaged Research, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Michelle A Ramos
- Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.,Center for Health Equity and Community Engaged Research, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Lynne D Richardson
- Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.,Center for Health Equity and Community Engaged Research, Icahn School of Medicine at Mount Sinai, New York, New York.,Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Gbenga Ogedegbe
- Department of Population Health, Center for Healthful Behavior Change, New York University School of Medicine, New York, New York
| | - Carol R Horowitz
- Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, New York, New York.,Center for Health Equity and Community Engaged Research, Icahn School of Medicine at Mount Sinai, New York, New York
| |
Collapse
|